Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has completed the acquisit...
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytoki...
Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint bl...
Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&t...
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...
Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare indust...
AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum The...
Carolina Molecular Inc., a leading molecular testing services laboratory, and Pixelgen Technologies AB announced a partnership to expand access to ...
- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, announced that the U.S...
Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...
LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...
Nurami Medical, a company developing next-generation regenerative solutions for soft tissue repair, has announced successful completion of Phase 1 of...
Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...
The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets...
© 2026 Biopharma Boardroom. All Rights Reserved.
